Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.
Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E; Efficacy Subgroup, RESIST-TB.
Dooley KE, et al.
Clin Infect Dis. 2012 Aug;55(4):572-81. doi: 10.1093/cid/cis487. Epub 2012 May 21.
Clin Infect Dis. 2012.
PMID: 22615332
Free PMC article.
Review.